Overall, these results highlight that ER-low positive BC present a substantially different response to neoadjuvant treatment as compared to classical ER-positive BCs, which usually present low pCR rates ranging between 7 and 16% according to grade18,21. The gene discussed is ESR1; the disease is breast cancer.